Sigilon Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sigilon Therapeutics, Inc. - overview
Established
2015
Location
Cambridge, MA, US
Primary Industry
Pharmaceuticals
About
Sigilon Therapeutics, Inc. is a biotechnology company based in the US, focused on developing innovative therapies utilizing its proprietary product platform to address unmet medical needs. Founded in 2015 in Cambridge, US, Sigilon Therapeutics, Inc. specializes in cell therapy development.
The company had a significant pivot when Eli Lilly and Company acquired it in June 2023 for USD 309. 60 mn, following a successful IPO in December 2020 that raised USD 126 mn. The co-founders, Daniel Anderson and Omid Veiseh, have backgrounds in biotechnology, contributing to the company's strategic direction and innovations. The current CEO is Rogério Vivaldi.
Sigilon Therapeutics, Inc. develops advanced cell therapies designed to treat chronic diseases and genetic disorders. Their proprietary platform enables the creation of cell-based therapies that can provide sustained delivery of therapeutic proteins, addressing various unmet medical needs in the healthcare sector. In 2022, Sigilon Therapeutics, Inc.
generated revenue of USD 12. 94 mn, with an EBITDA of USD -42. 39 mn for the same year, reflecting the company's focus on research and development. Following its acquisition in June 2023 by Eli Lilly and Company, Sigilon Therapeutics, Inc.
plans to utilize the raised funds to expand its cell therapy development initiatives. The company aims to introduce new products targeting chronic and genetic diseases, with specific plans to enter additional markets in North America and Europe by the end of 2024. This strategic focus is part of their broader goal to enhance therapeutic options available to patients.
Current Investors
Flagship Pioneering, Eli Lilly & Company
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.sigilon.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Sigilon Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | 22,800,000 | 43,900,000 | - | - | - |
| % Net Margin | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.